MT101-5

DRUG2 trials

Sponsors

Mthera Pharma Co., Ltd.

Conditions

Parkinson's Disease

Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

CompletedNCT05844787

Mthera Pharma Co., Ltd.Parkinson's Disease

Start: 2022-07-11End: 2023-02-23Updated: 2023-05-06

Phase 2

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

Not yet recruitingNCT06175767

Mthera Pharma Co., Ltd.Parkinson's Disease

Start: 2025-03-14End: 2025-09-30Target: 120Updated: 2024-11-25